PI: Dr. Gill

CRC: Kristine

The Butterfly Prostatic Retraction device is a novel transurethral implant designed to dilate the prostatic urethra and treat lower urinary tract symptoms. The purpose of this study is to demonstrate the safety and effectiveness of the Butterfly Device, in reducing Lower Urinary Tract Symptoms (LUTS) in patients who have Benign Prostatic Hyperplasia (BPH). The target population are males between the ages of 50 and up.

PI: Dr. Sonn

CRC: Satvir

The goal of this study is to use a clinical micro-ultrasound to systematically image the prostate before biopsy or surgery. The images from the ultrasound system will be saved and compared to other imaging modalities and pathology in order to develop better tools.

PI: Dr. Fan

CRC: Sneha

This is a pilot study to determine the feasibility of providing psychosocial and cardiac rehabilitation services to address socioeconomic health disparities and improve wellbeing for black men with prostate cancer. Black men have the highest prostate cancer incidence and mortality rates. Lifestyle interventions and psychological support have been documented to improve health in Black prostate cancer survivors, but studies are lacking in Black patients receiving active therapy. Anti-androgen therapies induce cardiovascular disease, hypertension, adiposity, sarcopenia, and metabolic syndrome. Thus we hypothesize that during active cancer treatment, psychological support, followed by cardiopulmonary training at an outpatient/tertiary cardiac rehabilitation center program will increase quality of life, mental health, cardiorespiratory fitness, and perhaps even cancer control.

PI: Dr. Khaki

CRC: Sneha

This is a Phase II/III trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy. The purpose of this study is to compare a usual treatment alone to using Durvalumab plus the usual treatment for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy. Participants taking part in this study will either get Durvalumab along with the usual approach cisplatin chemotherapy treatment for their cancer for up to eight weeks followed by surgery within 60 days, or will get the usual approach cisplatin chemotherapy treatment for up to eight weeks, followed by surgery within 60 days. If their kidneys function below the safe range to receive the usual approach with cisplatin, they will get Durvalumab plus gemcitabine for up to 12 weeks, followed by surgery.

PI: Dr. Srinivas

CRC: Sneha

This study will compare the standard chemotherapy regimen with an accelerated chemotherapy regimen using the same drugs to see if the accelerated chemotherapy regimen is beneficial but not more toxic than the standard chemotherapy regimen. Participants will be allocated to the two treatment arms in a ratio of 1:1.
•Arm A: Standard chemotherapy (bleomycin, etoposide, cisplatin, and pegfilgrastim or filgrastim) given in 3-week cycles.
•Arm B: Accelerated chemotherapy (bleomycin, etoposide, cisplatin, and pegfilgrastim or filgrastim) given in 2-week cycles, and followed by 4 weekly doses of bleomycin alone.

PI: Dr. Comiter

CRC: Julia

This study is assessing the real-world safety and effectiveness of the eCoin system in the treatment of urgency urinary incontinence. Overactive bladder syndrome (OAB) is a common clinical diagnosis that affects 7–27% of men and 9–43% of women worldwide. One of the most burdensome symptoms of OAB, urgency urinary incontinence (UUI), exerts a significant negative impact on quality of life for millions of Americans. Despite availability of first-line behavioral modifications and second-line medications, many patients are still undertreated. Third-line treatment options are underpenetrated as well because patients rarely progress to these therapies or have poor retention rates. The eCoin® (Valencia Technologies Corp., Valencia, CA) is an investigational, fully implanted, neuromodulation device indicated for the treatment of OAB with refractory UUI. It is intended to treat UUI by electrically stimulating the tibial nerve, which is presumed to improve or restore normal control of an imbalanced voiding reflex. 

PI: Dr. Sheth

CRC: Rachelle

Hydronephrosis is the most common abnormality found on prenatal ultrasounds, and is consequently one of the leading causes of referral to a pediatric urologist. Of these children, nearly 50% will have a diagnosis of ureteropelvic junction obstruction (UPJO), which can in severe cases lead to renal deterioration if left uncorrected. Unfortunately, the optimal timing of surgery for UPJO remains controversial, and current standard of care is to offer serial MAG-3 with Lasix renal scans to demonstrate deterioration of renal function prior to initiating surgery. Through the biochemical analysis of urine and blood samples at various stages of UPJO compared to the analysis of the urine and blood of healthy volunteers, we hope to identify a set of markers that will be able to predict the likelihood of renal deterioration in children with UPJO. This may allow pediatric urologists to better determine the optimal timing of UPJO surgery and allow the preservation of renal function in affected children.

PI: Dr. Han

CRC: Rachelle

The purpose of this study is to understand if ultrasound imaging using microbubbles as a contrast agent is useful in checking kidney morphology and function. We hope to understand if contrast enhanced ultrasound imaging with microbubbles is useful in checking kidney morphology and function. This new knowledge may allow us to potentially identify an imaging modality that can be used to check kidney morphology and function without the use of a radiopharmaceutical or radioisotope (required for MAG3 or DMSA scans) and could be a potentially more cost-effective option for kidney imaging.

PI: Dr. Kan

CRC: Rachelle

Pediatric lower urinary tract symptoms significantly impact children's health as well as their emotional, social, physical, and academic domains due to associated urinary symptoms, lowering their quality of life. Behavioral modifications have been identified as an effective measure to educate children and their families on strategies to rehabilitate the bladder and sphincter function to achieve more sustainable voiding habits and have been shown to reduce pLUTS in 40-70% of patients. Hence, the Bladder Basics was developed as a self-guided digital health platform to provide fun and engaging education on managing pLUTS that patients would receive in a traditional clinical encounter in an accessible manner to patients and their families. Bladder Basics is designed to be a digital health education tool to improve knowledge of healthy bladder practices. It includes a set of educational videos/lessons to deliver bladder health education on various topics, such as knowing our bladder, why our bladder becomes unhappy, and how to make our bladder happy. In-video activities were also provided to increase learning engagement and facilitate learning. Participants are expected to complete the entire Bladder Basics course within 1 month.